Designer Exosomes for Targeted Delivery of a Novel Therapeutic Cargo to Enhance Sorafenib-Mediated Ferroptosis in Hepatocellular Carcinoma

Sorafenib is one of the few effective first-line drugs approved for the treatment of advanced hepatocellular carcinoma (HCC). However, the development of drug resistance is common among individuals with HCC. Recent evidence indicated that the anticancer activity of sorafenib mainly relies on the ind...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Xiaoju Li, Qianqian Yu, Runze Zhao, Xinyan Guo, Chenlin Liu, Kuo Zhang, Wangqian Zhang, Jinghan Liu, Jinzheng Yu, Shuning Wang, Qiang Hao, Weina Li, Wei Zhang, Meng Li, Yingqi Zhang, Cun Zhang, Yuan Gao
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-06-01
Colecção:	Frontiers in Oncology
Assuntos:	hepatocellular carcinoma resistance sorafenib engineered exosome ferroptosis
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2022.898156/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!